Phase 3 Obesity Trial, Recruiting NCT07297290 Sponsor: University Of Nigeria Teaching Hospital Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT07297290
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with a body mass index (BMI) of 30 or higher, which is the medical measure used to classify obesity
  • People whose fasting blood sugar level is below 7.0 mmol/L (a blood sugar reading taken after not eating for a period of time)
  • People who have not used any prescribed or medical treatments for weight loss in the past 12 months
  • People who are not currently taking part in another clinical trial

Who may not be able to join:

  • People whose BMI is below 30
  • People whose fasting blood sugar level is 7.0 mmol/L or higher
  • People who have used medical treatments for weight control within the last 12 months
  • People who are currently enrolled in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: IFEYINWA D NNAKENYI, MD, University Of Nigeria Teaching Hospital

Phone: +2347031800855

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University Of Nigeria Teaching Hospital
Registry
ClinicalTrials.gov
Start date
23 July 2025
Est. completion
31 March 2027

Where this trial is recruiting

Nigeria

Primary endpoints

Effect of Metformin on body weight change; Effect of Metformin on Cardiovascular risk; Effect of Metformin on insulin resistance in non-diabetics; Effect of metformin on waist circumference change; Effect of metformin on waist-to-hip circumference change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov